Research Analysts’ Weekly Ratings Updates for BridgeBio Pharma (BBIO)

BridgeBio Pharma (NASDAQ: BBIO) recently received a number of ratings updates from brokerages and research firms:

• 8/12/2026 – BridgeBio Pharma had its price target raised by Truist Financial Corporation from $102.00 to $107.00. They now have a “buy” rating on the stock.
• 8/12/2026 – BridgeBio Pharma had its price target raised by Canaccord Genuity Group Inc. from $104.00 to $106.00. They now have a “buy” rating on the stock.
• 8/12/2026 – BridgeBio Pharma had its price target raised by JPMorgan Chase & Co. from $100.00 to $111.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – BridgeBio Pharma was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 8/11/2026 – BridgeBio Pharma had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $110.00 price target on the stock.
• 8/11/2026 – BridgeBio Pharma had its price target raised by Bank of America Corporation from $101.00 to $104.00. They now have a “buy” rating on the stock.
• 8/11/2026 – BridgeBio Pharma had its price target lowered by Morgan Stanley from $98.00 to $97.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – BridgeBio Pharma had its price target raised by TD Cowen from $95.00 to $110.00. They now have a “buy” rating on the stock.
• 8/11/2026 – BridgeBio Pharma had its price target raised by Wells Fargo & Company from $98.00 to $102.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – BridgeBio Pharma had its price target raised by Piper Sandler from $111.00 to $115.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – BridgeBio Pharma had its price target raised by Citigroup Inc. from $82.00 to $93.00. They now have a “neutral” rating on the stock.
• 7/13/2026 – BridgeBio Pharma had its price target raised by HC Wainwright from $110.00 to $120.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In related news, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the sale, the chief accounting officer directly owned 127,401 shares of the company’s stock, valued at $10,199,724.06. This represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $84.03, for a total transaction of $840,300.00. Following the transaction, the chief executive officer directly owned 505,686 shares of the company’s stock, valued at $42,492,794.58. This represents a 1.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 387,343 shares of company stock worth $30,289,400. 14.23% of the stock is currently owned by insiders.

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.